Inovio Pharmaceuticals got fast approval from the FDA for its drug VOCERYQ to help cut down surgeries for adults.

Nov 2, 2026, 7:21 AM ETTrialRead the original at SEC EDGAR

Good for INO

The FDA approved VOCERYQ to reduce how often adults with RRP need surgery, giving Inovio a path to offer the treatment. Continued approval may depend on a study confirming clinical benefit.

INO · Inovio Pharmaceuticals, Inc.

AI read · Good for INO

The AI's read

The approval gives Inovio a way to offer a treatment intended to reduce surgery for adults with RRP. The company expects to start shipping in about 60 days and reach full field coverage in Q1 2027. Continued approval may depend on a follow-up study confirming clinical benefit, so the opportunity comes with an important condition.

Get alerts for INO

Follow Inovio Pharmaceuticals, Inc. (INO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INO

Free on the App Store and Google Play, or on the web.